BOSTON– Orum Therapeutics has appointed Maria Koehler, M.D., Ph.D., and Geoff Meyerson to its Board of Directors, adding clinical development and strategic investment expertise as the company advances its pipeline of degrader-antibody conjugate programs.
The appointments were approved at the company’s annual general meeting on March 27, 2026. Orum is developing therapies based on degrader-antibody conjugates, or DACs, including programs targeting GSPT1, as it seeks to expand applications in oncology and other diseases.
“Maria and Geoff join Orum at an important point in the Company’s evolution,” said Sung Joo (SJ) Lee, Ph.D., founder and CEO of Orum. “As we advance our next wave of DAC programs to the clinic and continue to broaden our payload capabilities, their perspectives will be highly valuable. Maria brings deep experience across oncology clinical development, translational medicine, biomarker strategy, and regulatory execution. Geoff brings a strong record in company building, partnering, and strategic transactions across the life sciences. Together, they strengthen our Board as we continue building Orum into a leading DAC company.”
Koehler is an oncology biotech executive and hematologist/oncologist with more than 20 years of experience spanning clinical development, regulatory strategy, and translational oncology. She most recently served as a venture partner at Omega Funds and senior advisor to Viking Global, and previously was chief medical officer at Repare Therapeutics. Her earlier roles include chief medical officer at Bicycle Therapeutics and senior oncology development positions at Pfizer, GSK, and AstraZeneca, where she contributed to the development of IBRANCE (palbociclib). She has authored more than 170 peer-reviewed publications and has served on several public and private company boards.
“Orum has built a compelling approach to targeted protein degradation by combining the precision of antibodies with the catalytic potential of degrader payloads,” said Dr. Koehler. “I am pleased to join the Board as the company advances its DAC pipeline to the clinic, and I look forward to supporting the team as it works to translate this science into meaningful new therapeutic options for patients.”
Meyerson is a life sciences entrepreneur and advisor with experience in investment banking, venture capital, and company formation. He is co-founder and CEO of Locust Walk and has also co-founded Franklin Life Science, Venning Life Sciences, and BioBreak. His background includes expertise in mergers and acquisitions, business development, venture investing, and growth strategy.
“What stands out about Orum is that the company has established a differentiated position in DACs, with strong scientific foundations and multiple paths to value creation across its platform and pipeline,” said Meyerson. “I am excited to join the Board and support the management team as the company advances its programs, expands its strategic reach, and works to realize the broader potential of its technology.”
